Exelixis (EXEL) AI Stock Analysis

• Market Cap: $10.08B
• Dividend Yield: N/A
• Average Volume (3M): 3.71M
• Price to Earnings (P/E): 18.0
• Beta (1Y): 0.87
• Revenue Growth: 10.73%
• EPS Growth: 81.66%
• Country: US
• Employees: 1,147
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): 0.75
• Shares Outstanding: 269,202,500
• 10 Day Avg. Volume: 5,298,169
• 30 Day Avg. Volume: 3,712,084
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.18
• Enterprise Value/Revenue: 5.35
• Enterprise Value/Gross Profit: 5.54
• Enterprise Value/Ebitda: 14.93
• 1Y Price Target: $44.72
• Price Target Upside: 19.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 20

• Rating: 73 Outperform
• Price Target: $41.00 ▲(9.45% Upside)

Exelixis demonstrates strong financial performance and a positive outlook from recent earnings. However, technical indicators suggest near-term challenges. Valuation remains moderate, supporting a stable investment thesis.

Positive Factors

Financial Guidance

Exelixis raised 2025 revenue guidance to $2.25-2.35B due to strong Cabo sales, indicating confidence in future performance.

Market Performance

Cabo market share grew to 45% and increased 18% TRx YoY growth, outperforming the TKI market.

Market Share

The launch of NET has rapidly captured a 35% market share in less than four months, demonstrating strong market penetration.

Negative Factors

Drug Development

The decision not to advance zanza in the STELLAR-305 trial could exacerbate concerns about its competitiveness against cabo.

Financial Performance

Q2 revenues of $568M missed the consensus estimate of $578M, leading to potential investor disappointment.

Investor Sentiment

Investors are less confident in zanza's potential due to the 'no-go' decision in HNSCC, and the cabo performance coming in below expectations.

Exelixis Business Overview & Revenue Model

Company Description

Exelixis, Inc. is a biotechnology company focused on discovering, developing, and commercializing new medicines to enhance care and outcomes for patients with cancer. Operating primarily in the biopharmaceutical sector, Exelixis is best known for its flagship product, CABOMETYX (cabozantinib), a medication used in the treatment of various forms of cancer, including renal cell carcinoma and hepatocellular carcinoma. The company continues to engage in research and development activities to expand its portfolio of oncology therapies.

How the Company Makes Money

Exelixis primarily generates revenue through the sale of its proprietary cancer treatments, notably CABOMETYX. The company earns money by marketing and distributing these drugs both directly and through strategic partnerships with pharmaceutical companies. A significant portion of its revenue is derived from product sales within the United States, while international sales further contribute to its financial performance. Exelixis also benefits financially from collaborations with other organizations, receiving milestone payments, royalties, and licensing fees. These partnerships help expand the reach of its products and support ongoing research and development efforts to bring new therapies to market.

Exelixis Financial Statement Overview

Summary

Exelixis demonstrates strong financial performance with significant revenue growth, robust profitability margins, and effective cash generation. The balance sheet is healthy with low leverage, although there's a slight decline in stockholders' equity.

Income Statement

Exelixis demonstrates strong revenue growth, with a TTM revenue increase of 6% over the previous year. The company maintains high gross and net profit margins at 96.8% and 28.0% respectively for TTM, reflecting efficient cost management. Additionally, the EBIT and EBITDA margins are robust at 33.1% and 36.7%, indicating solid operational performance.

Balance Sheet

The balance sheet is strong, with a low debt-to-equity ratio of 0.09, suggesting conservative leverage levels. The equity ratio is a healthy 75.1%, showcasing a solid financial foundation. However, stockholders' equity has seen a slight decline over the past year, necessitating monitoring.

Cash Flow

Operating cash flow is robust, with a TTM to net income ratio of 1.31, indicating effective cash generation relative to earnings. Free cash flow has grown significantly by 28.3% from the previous period, supporting financial flexibility and potential reinvestment.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.17B	1.83B	1.61B	1.43B	987.54M
Gross Profit	2.09B	1.76B	1.55B	1.38B	951.27M
EBITDA	718.75M	196.60M	222.36M	300.30M	119.20M
Net Income	521.27M	207.76M	182.28M	231.06M	111.78M
Balance Sheet
Total Assets	2.95B	2.94B	3.07B	2.62B	2.14B
Cash, Cash Equivalents and Short-Term Investments	1.11B	995.30M	1.31B	1.47B	1.21B
Total Debt	215.83M	189.94M	190.17M	51.27M	49.09M
Total Liabilities	703.49M	678.45M	583.06M	405.62M	258.22M
Stockholders Equity	2.24B	2.26B	2.49B	2.21B	1.88B
Cash Flow
Free Cash Flow	633.79M	170.35M	224.16M	336.58M	178.64M
Operating Cash Flow	699.97M	333.32M	362.61M	400.80M	208.98M
Investing Cash Flow	-116.78M	-26.95M	-524.41M	-42.88M	-131.22M
Financing Cash Flow	-628.81M	-546.05M	586.00K	-14.80M	-25.13M

Exelixis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 37.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EXEL, the sentiment is Negative. The current price of 37.46 is below the 20-day moving average (MA) of 42.42, below the 50-day MA of 42.69, and above the 200-day MA of 37.36, indicating a neutral trend. The MACD of -1.69 indicates Positive momentum. The RSI at 34.91 is Neutral, neither overbought nor oversold. The STOCH value of 12.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EXEL.

Exelixis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BMRN	79 Outperform	$11.88B	18.34	11.62%	―	17.99%	152.10%
HALO	79 Outperform	$7.49B	16.13	147.06%	―	25.65%	57.10%
CORT	78 Outperform	$7.42B	62.76	21.42%	―	25.71%	4.48%
INCY	75 Outperform	$15.18B	17.65	24.30%	―	18.87%	1088.27%
EXEL	73 Outperform	$10.08B	17.97	29.00%	―	10.73%	81.66%
Sector *	51 Neutral	$7.38B	0.53	-62.86%	2.36%	15.62%	-0.90%
ASND	43 Neutral	$11.27B	―	357.68%	―	10.69%	34.71%

Exelixis Corporate Events

Exelixis Holds Annual Meeting, Elects New Directors

On May 28, 2025, Exelixis held its Annual Meeting via live webcast, where stockholders elected 11 directors to serve until the next annual meeting in 2026. Additionally, stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending January 2, 2026, and approved the executive compensation proposal.

The most recent analyst rating on (EXEL) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Exelixis stock, see the EXEL Stock Forecast page.